US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.47

+0.08000.16%

Post-market: 50.470.00000.00%16:10 EDT

Volume:134.59K

Turnover:6.81M

Market Cap:15.43B

PE:22.63

High:50.80

Open:50.40

Low:50.25

Close:50.39

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.38

T/O Rate:0.04%

Dividend:2.11

Dividend Rate:4.18%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.65

PE(LYR):20.47

Loading ...

Overview Company News Filings

GSK announces momelotinib granted ODD from U.S. FDA, EMA

Press Release: Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

Cardano Price Hits All-Time Low: Why Charles Hoskinson's Project Failed

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease

Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program

MT Newswires Live

Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe

MT Newswires Live

Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/EMA/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.47,"timestamp":1787688000000,"preClose":50.39,"halted":0,"volume":134592,"hourTrading":{"tag":"盘后","latestPrice":50.47,"preClose":50.47,"latestTime":"16:10 EDT","volume":716,"amount":36136.52,"timestamp":1787688604810,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.001587616590593338,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Post-Mkt","change":0.08,"latestTime":"08-25 16:53:52 EDT","open":50.4,"high":50.8,"low":50.25,"amount":6806174,"amplitude":0.010915,"askPrice":51.45,"askSize":38,"bidPrice":49.83,"bidSize":8,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"exchange":"NYSE","adjPreClose":50.39,"dividendRate":0.041782,"postHourTrading":{"tag":"盘后","latestPrice":50.47,"preClose":50.47,"latestTime":"16:10 EDT","volume":716,"amount":36136.52,"timestamp":1787688604810,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.382598,"impliedVol":0.3796,"impliedVolPercentile":0.9562},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.382598,"shares":305783111,"dividePrice":2.112018,"high":50.8,"amplitude":0.010915,"preClose":50.39,"low":50.25,"week52Low":45.77,"pbRate":"1.65","psRate":"2.39","week52High":55.49,"institutionHeld":0,"latestPrice":50.47,"committee":-0.652174,"eps":2.229761,"divideRate":0.041847,"volume":134592,"delay":0,"ttmEps":2.229761,"open":50.4,"prevYearClose":49.24,"prevWeekClose":50.08,"prevMonthClose":53.89,"prevQuarterClose":53.02,"fiveDayClose":51.46,"twentyDayClose":54.46,"sixtyDayClose":52.16,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778472000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-08-24","current":22.634713,"percent":0.577922,"low":16.637027,"twenty":17.636831,"median":20.208641,"eighty":21.049566,"high":22.07626,"avg":19.79539,"sd":1.501126,"marketCap":15329017705.45},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-24","current":20.387446,"twenty":17.636831,"median":20.208641,"eighty":21.049566,"marketCap":15329017705.45}],"updateTime":1787691232588},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642267278","title":"GSK announces momelotinib granted ODD from U.S. FDA, EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267278?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:07","pubTimestamp":1781262453,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced that momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation, ODD, from th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK","BK4007","BK4585","BK4183","EMA","GSK.UK","GSKH","BK4081","LU1829250122.USD","ODD","BK4588","IE0009354923.USD","BK4532","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642023976","title":"Press Release: Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2642023976","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642023976?lang=en_us&edition=fundamental","pubTime":"2026-06-12 03:31","pubTimestamp":1781206260,"startTime":"0","endTime":"0","summary":"-- Doc Pharma financial profile: approximately $24 million asset base,approximately $6.7 million in average annual revenue and approximately. -- Immediately accretive: expected to support margin expansion,-- Deepens vertical integration: expected to drive synergies, optimized. production, economies of scale, expanded capacity, and a strengthened R&D. square feet, built to the highest European standards, providing a clear. -- Manufacturing excellence: a broad range of dosage forms, certified to GMP,ISO, Kosher, and Halal standards, with site registrations for the UAE,-- Boosts product portfolio: adds advanced and branded generics and OTC. CHICAGO, June 11, 2026  -- Cosmos Health Inc.  , a diversified, vertically integrated global healthcare group, today announced that it has entered into a non-binding letter of intent  to acquire 100% of Doc Pharma S.A. , a fully licensed GMP pharmaceutical manufacturer.Doc Pharma operates an approximately 59,000-square-foot, GMP-licensed production fac","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4175","EMA","COSM","EPV","BK4232","BK4022","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642402214","title":"Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642402214","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642402214?lang=en_us&edition=fundamental","pubTime":"2026-06-11 16:00","pubTimestamp":1781164800,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, June  11, 2026  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310224/0/en/Oculis-to-Present-Privosegtor-at-Upcoming-Clinical-Trials-at-the-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2271345857.HKD","ON","LU1854103824.USD","SMMF","LU2487616109.SGD","EMA","LU1668664300.SGD","LU0724618433.USD","LU2089284900.SGD","LU1861220033.SGD","LU1989772840.SGD","LU1363072403.SGD","BK4605","LU0106261372.USD","LU0528227936.USD","LU1732799900.SGD","LU2028103732.USD","LU2111349929.HKD","LU1791710582.SGD","BK4081","BK4581","LU1720051017.SGD","LU0006306889.USD","LU0390134368.USD","LU0795875086.SGD","OCS","LU0912757837.SGD","LU2357305700.SGD","LU0225283273.USD","LU2360107325.USD","LU1244550221.USD","LU0106831901.USD","LU1244550577.SGD","LU0210528500.USD","LU2023251221.USD","LU1861214812.USD","LU0348723411.USD","LU0314104364.USD","BK4516","LU0320765646.SGD","LU1064131342.USD","LU0795875169.SGD","BK4534","LU1989772923.USD","BK4211","LU0267386448.USD","LU2133065610.SGD","LU1861219969.SGD","LU1978683503.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642022134","title":"Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642022134","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642022134?lang=en_us&edition=fundamental","pubTime":"2026-06-11 16:00","pubTimestamp":1781164800,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310226/0/en/Oculis-to-Present-Privosegtor-at-Upcoming-Clinical-Trials-at-the-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1989772923.USD","OCS","LU1854103824.USD","LU0557290698.USD","LU0912757837.SGD","LU0390134368.USD","LU0971096721.USD","LU2089283258.USD","LU1244550577.SGD","LU2264538146.SGD","LU2298322129.HKD","LU0158827781.USD","LU0267386448.USD","LU1363072403.SGD","LU1978683503.SGD","LU2111349929.HKD","LU2271345857.HKD","LU0006306889.USD","LU1989772840.SGD","BK4127","LU2357305700.SGD","IE00BKVL7J92.USD","LU1732800096.USD","LU1791710400.SGD","LU1861219969.SGD","LU1548497426.USD","SMMF","LU0348723411.USD","BK4534","LU1854104046.USD","LU2028103732.USD","LU0882574139.USD","LU1162221912.USD","LU1791710582.SGD","LU0314104364.USD","EMA","LU2133065610.SGD","LU2360107325.USD","BK4007","LU0724618433.USD","LU1861215975.USD","LU1988902786.USD","IE00BD6J9T35.USD","ON","LU0053666078.USD","LU1732799900.SGD","IE00BFMHRM44.USD","LU1668664300.SGD","BK4605"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642209429","title":"MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642209429","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642209429?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:15","pubTimestamp":1781097300,"startTime":"0","endTime":"0","summary":"Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $7","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309785/0/en/MAIA-Biotechnology-Activates-and-Opens-Enrollment-at-Second-U-S-Clinical-Site-for-International-Phase-2-THIO-101-Expansion-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","L","CPI","BK4139","LU2487616109.SGD","LU0053666078.USD","LU0210528500.USD","MAIA","BK4585","BK4081","EMA","BK4107","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293144","title":"Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293144","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642293144?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:00","pubTimestamp":1781096400,"startTime":"0","endTime":"0","summary":"Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2.Record operational momentum: CosmoFarm wholesale distribution and GMP-certif","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309738/0/en/Cosmos-Health-CEO-Issues-Letter-to-Shareholders-Building-an-Innovative-AI-Driven-Global-Healthcare-Platform-Record-Growth-with-U-S-Expansion-Underway.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","ARTY","BK4585","EMA","LU0128526141.USD","COSM","AIPO","LU0029874061.USD","BK4081","AGIX","LABU","XBI","BK4581","XLV","BK4588","BK4175","CHAT","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498269","title":"Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498269","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498269?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:20","pubTimestamp":1781011200,"startTime":"0","endTime":"0","summary":"MIAMI, June  09, 2026  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-rel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308957/0/en/Longeveron-Granted-Small-or-Medium-sized-Enterprise-SME-Status-by-the-European-Medicines-Agency-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4575","EMA","BK4081","BK4150","BK4139","MSC","MDCO","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642436001","title":"Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2642436001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642436001?lang=en_us&edition=fundamental","pubTime":"2026-06-09 02:45","pubTimestamp":1780944300,"startTime":"0","endTime":"0","summary":"Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3308406/0/en/Oculis-to-Present-at-the-47th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","LU1804176565.USD","BK4550","IE0004086264.USD","BK4141","LU0348723411.USD","LU0106831901.USD","LU0868494708.USD","LU0096364046.USD","LU1668664300.SGD","BK4581","IE00BD6J9T35.USD","LU2237443978.SGD","OCS","LU1868836591.USD","ON","LU2750360997.AUD","EMA","LABU","LU1868837136.USD","IE0004091025.USD","IE00BSNM7G36.USD","LU2237443382.USD","IE00BFXG1179.USD","LU1868837300.USD","LU2237443549.SGD","LU0345770308.USD","LU2237443465.HKD","LU1861214812.USD","XLV","LU2471134879.HKD","LU1861220033.SGD","LU1868836757.USD","LU1854103824.USD","GSX","LU0048573561.USD","LU2357305700.SGD","HCSG","BK4552","LU0128526141.USD","LU2471134523.USD","BK4585","LU1791807156.HKD","XBI","BK4137","LU1720051017.SGD","LU1861219969.SGD","LU1978683503.SGD","LU0345770993.USD","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641063124","title":"Cardano Price Hits All-Time Low: Why Charles Hoskinson's Project Failed","url":"https://stock-news.laohu8.com/highlight/detail?id=2641063124","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641063124?lang=en_us&edition=fundamental","pubTime":"2026-06-06 23:47","pubTimestamp":1780760863,"startTime":"0","endTime":"0","summary":"Cardano (CRYPTO: ADA) price retreated for the fourth consecutive weeks and reached a record low, continuing a downward spiral that started in September 2021 when it pe","market":"nz","thumbnail":"https://www.benzinga.com/files/images/story/2026/06/06/Cardano-Cryptocurrencies-And-Graph-Stati.jpeg","type":0,"news_type":0,"thumbnails":["https://www.benzinga.com/files/images/story/2026/06/06/Cardano-Cryptocurrencies-And-Graph-Stati.jpeg"],"rights":{"source":"Benzinga","url":"https://www.benzinga.com/crypto/cryptocurrency/26/06/53047638/cardano-price-hits-all-time-low-why-charles-hoskinsons-project-failed","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/crypto/cryptocurrency/26/06/53047638/cardano-price-hits-all-time-low-why-charles-hoskinsons-project-failed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"Benzinga","symbols":["BK4081","BKCH","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641437911","title":"Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories","url":"https://stock-news.laohu8.com/highlight/detail?id=2641437911","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641437911?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:25","pubTimestamp":1780665900,"startTime":"0","endTime":"0","summary":"Science-backed, USDA and EU-certified, whole olive tree supplement for two major wellness categories — rapidly growing global market projected to exceed $33 billionOliv18 expands the 18 Series with a ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307433/0/en/Cosmos-Health-Continues-U-S-Expansion-with-Launch-of-Oliv18-Targeting-Cardiovascular-and-Antioxidant-Categories.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","BK4175","BK4081","BK4232","BK4082","EMA","CSII","PAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640938168","title":"Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2640938168","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640938168?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:25","pubTimestamp":1780579500,"startTime":"0","endTime":"0","summary":"Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 millionProceeds could fund a mea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306858/0/en/Cosmos-Health-Identifies-Approximately-20-Million-in-Non-Core-Assets-Available-for-Monetization-to-Accelerate-Growth-and-Unlock-Shareholder-Value.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4175","COSM","BK4081","EMA","AAQC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951227","title":"Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951227","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951227?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:25","pubTimestamp":1780316700,"startTime":"0","endTime":"0","summary":"CHICAGO, June  01, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the exte","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304348/0/en/Cosmos-Health-Enters-69-Billion-Global-Animal-Health-Industry-with-Veterinary-C-Scrub-Wash-4-Following-Successful-European-Standard-Testing-Under-EN-1656-and-EN-1657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","COSM","BK4124","BK4175","BK4081","EMA","SMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989428","title":"Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989428","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989428?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303964/0/en/Ascentage-Pharma-Presents-Data-on-Olverembatinib-in-CML-LBP-and-Ph-BCP-ALL-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU2355687059.USD","AAPG","BK4588","BK4139","CR","EMA","BK4161","LU1699723380.USD","BK4107","BK4533","LU0985320562.USD","ALL","BK4585","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989426","title":"Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989426","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989426?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303966/0/en/Ascentage-Pharma-Presents-Updated-Clinical-Data-for-Olverembatinib-as-Second-Line-Therapy-in-CML-CP-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU1989763690.USD","LU1989763427.SGD","AAPG","LU1261432733.SGD","BK4016","CP","EMA","BK4081","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698491","title":"Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698491","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698491?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"XanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026SYDNEY, May  28, 2026  (GLOBE NEWSWIRE) -- Actinogen Medical Limit","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302808/0/en/Actinogen-receives-positive-EMA-scientific-advice-aligned-with-prior-FDA-guidance-for-its-Alzheimer-s-disease-program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","AD","EMA","BK4585","BK4081","BK4156","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656566","title":"Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656566","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656566?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:43","pubTimestamp":1779936180,"startTime":"0","endTime":"0","summary":"Coronary artery disease  remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard of care therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable CAD, even when treated with optimized treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients. Consequently, there is a significant unmet medical need for novel antithrombotic approaches that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk.\"We are very pleased to advance our anti-thrombotic siRNA programs into the next stage of clinical development in Europe. This milestone reflects ","market":"us","thumbnail":"https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ribo-announces-phase-2-clinical-trial-submission-to-ema-further-advancing-sirna-therapeutics-in-thromboembolic-disease-302783857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK7504","BK4539","LENZ","BK4007","CAD.AU","BK7095","EMA","BK4139","EMA.AU","BK7129","CTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653254","title":"Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653254","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653254?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:53","pubTimestamp":1779933233,"startTime":"0","endTime":"0","summary":"Actinogen Medical  reached a common understanding of the pathway to marketing approval for its Alzheimer's disease program in its scheduled scientific advice meeting with the European Medicines Agency , according to a Thursday Australian bourse filing.The understanding includes the specification of regulatory starting materials for the commercial manufacturing of Xanamem  drug substance, design considerations for an additional pivotal clinical trial, as well as the limited number of ancillary clinical pharmacology trials and nonclinical studies required.The understandings also include ensuring the proposed makeup of the planned safety database is consistent with EMA and US Food and Drug Administration  guidelines.The firm said the understandings align closely with the guidance received at an earlier meeting with the US FDA's Neurology-I division.Actinogen Medical's shares rose nearly 3% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA","ACW.AU","BK7067","EMA.AU","BK7508","EPV","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653364","title":"Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653364?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:33","pubTimestamp":1779932024,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938","BK4081","EMA.AU","BK1161","BK7129","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638342006","title":"Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638342006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638342006?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:57","pubTimestamp":1779922637,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. Class H ( ($HK:6938) ) just unveiled an announcement. Suzhou Ribo Life Science Co., Ltd. has advanced its cardio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-cad-sirna-drug-with-ema-phase-ii-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-cad-sirna-drug-with-ema-phase-ii-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638168897","title":"AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration","url":"https://stock-news.laohu8.com/highlight/detail?id=2638168897","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638168897?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:47","pubTimestamp":1779886020,"startTime":"0","endTime":"0","summary":"Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Inve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301981/29489/en/AIM-ImmunoTech-Announces-Emerging-Ebola-Opportunity-for-Ampligen-Amid-Escalating-Global-Health-Concerns-and-WHO-Emergency-Declaration.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4139","BK4557","AIM","BK4081"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}